Tin tức & Cập nhật
Xem bài viết Niệu khoa
Xem

Metastatic prostate cancer risk low in older men nearing age limit for PSA screening
Older men who have had prostate-specific antigen (PSA) testing and are approaching the age limit for recommended screening appear to have a relatively low risk of developing metastatic or fatal prostate cancer, suggests a recent study.

NIAGARA interim data support perioperative durvalumab for MIBC
In a preplanned interim analysis of the NIAGARA trial, the addition of durvalumab to neoadjuvant chemotherapy prior to radical cystectomy (RC) and durvalumab monotherapy following surgery confers a survival advantage over chemo alone for muscle-invasive bladder cancer (MIBC).

Darolutamide + ADT, without docetaxel, shows efficacy benefits in mHSPC
Darolutamide plus androgen-deprivation therapy (ADT), without docetaxel, improves radiological progression-free survival (rPFS) and secondary efficacy outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to results of the global phase III ARANOTE trial presented at ESMO 2024.

Cruciferous vegetables help avert recurrence in NMIBC patients on BCG
Higher consumption of raw cruciferous vegetables appears to reduce the risk of recurrence in nonmuscle-invasive bladder cancer (NMIBC) patients treated with induction bacillus Calmette-Guérin (BCG), suggests a study.

Enzalutamide edges out abiraterone in mCRPC
In the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the use of enzalutamide yields small improvements in outcomes when compared with abiraterone acetate, according to a retrospective study.



